LIBVYRA
Live / Registered — Registered (as of 18 Jun 2024)
What this means for you
Registered since 18 Jun 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97545134
- Registration number
- 7417127
- Mark type
- Stylized text
- Filed
- 11 Aug 2022
- Published for opposition
- 02 Apr 2024
- Registered
- 18 Jun 2024
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 18 Jun 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 18 Jun 2024 — REGISTERED-PRINCIPAL REGISTER
- 02 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Apr 2024 — PUBLISHED FOR OPPOSITION
- 13 Mar 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 22 Feb 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Jan 2024 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
- 29 Sept 2023 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 12 Jul 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 12 Jul 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 12 Jul 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 01 Jun 2023 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 01 Jun 2023 — LETTER OF SUSPENSION E-MAILED
- 01 Jun 2023 — SUSPENSION LETTER WRITTEN
- 30 May 2023 — ASSIGNED TO EXAMINER